5 Key Takeaways

• 1

  Selective laser trabeculoplasty (SLT) is emerging as a preferred first-line therapy for glaucoma, redefining treatment paradigms.

• 2

  Topical medical therapy has been the standard for over 150 years, but its limitations include high nonadherence and ocular surface disease.

• 3

  The LiGHT trial demonstrated that SLT significantly reduces the risks of glaucoma progression and surgery compared to medical therapy.

• 4

  SLT offers a drop-free lifetime of glaucoma care for many patients, with 70% maintaining controlled IOP without medication at 6 years.

• 5

  The adoption of SLT is increasing in the U.S., supported by new technologies like direct SLT and expanded optometric practice scopes.